NAD+ Decline and Aging: NMN vs NR — What the Evidence Says
A head-to-head comparison of the two leading NAD+ precursors based on current clinical evidence, bioavailability data, and practical considerations.
April 1, 20268 min read
Public
The NAD+ Problem
NAD+ (nicotinamide adenine dinucleotide) is essential for over 500 enzymatic reactions. Levels decline approximately 50% between ages 40-60, correlating with metabolic dysfunction, DNA damage accumulation, and mitochondrial decline.
NMN: Direct Precursor
Advantages
One enzymatic step closer to NAD+ than NR
Dedicated transporter (Slc12a8) identified in 2019
Strong preclinical data from David Sinclair's lab
Multiple positive human clinical trials
Clinical Evidence
Increased NAD+ levels in healthy adults (Yi et al., 2023)
Improved insulin sensitivity in overweight women (Yoshino et al., 2021)
Enhanced aerobic capacity in amateur runners (Liao et al., 2022)
NR: The Established Contender
Advantages
Longer track record of human research
FDA GRAS status since 2016
Clear oral bioavailability data
Commercially available as Niagen/Tru Niagen
Clinical Evidence
Safely increases NAD+ in healthy middle-aged adults (Martens et al., 2018)
May improve systolic blood pressure (Martens et al., 2018)
Mixed results on functional outcomes in older adults
Head-to-Head
No direct human comparison trial exists. Preclinical data from the Bhatt lab (2024) suggested NMN was superior for NAD+ elevation in liver, but NR was better in muscle. The practical difference for humans remains uncertain.
Our Take
Both NMN and NR effectively raise NAD+ levels. NMN may have a slight theoretical edge due to its proximity to NAD+ in the biosynthetic pathway, but NR has more established long-term safety data. Cost, availability, and individual response may matter more than the precursor choice itself.